Plain-English translation of NCT05856383 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a combination of three medications—inetetamab, pyrotinib, and vinorelbine—to treat advanced HER2-positive breast cancer in real-world conditions. Researchers want to learn how well this medication combination works and how safe it is for patients whose cancer has spread or cannot be surgically removed. The study will follow about 100 patients and track how they respond to the treatment.
Advanced HER2-positive breast cancer is an aggressive form of cancer that needs new treatment options. This study exists to see whether combining these three medications together might be more effective than existing approaches, and to understand what side effects patients might experience.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive the three-medication combination as your breast cancer treatment. The study has three phases: first, a screening period where doctors confirm you qualify; then the treatment period where you receive the medication; and finally a follow-up period where researchers track how you're doing and monitor for any side effects. You'll need to attend regular clinic visits for check-ups, blood tests, and imaging scans to see how well the treatment is working.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China
Sponsor
Zhejiang Cancer Hospital
Enrollment target
~100 participants
Started
March 2022
Primary completion
December 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Chen zhanhong
Zhejiang Cancer Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.